← Back to patent-cliff list
Salbutamol metered-dose inhalation(AstraZeneca)
Tier C — Watch / tradeSalbutamol metered-dose inhalation(AstraZeneca)
Pearl Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB2
Indications (approved)：Asthma
Regional status
US
Phase II
2025-02-10
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Salbutamol metered-dose inhalation(AstraZeneca)?
Approved indications include: Asthma.
When does the Salbutamol metered-dose inhalation(AstraZeneca) patent expire?
No public expiry year is available for Salbutamol metered-dose inhalation(AstraZeneca) yet; this page updates once verified.
How do I get a quote for Salbutamol metered-dose inhalation(AstraZeneca) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01